Farmak AG acquired a 100% stake in the Polish pharmaceutical company Symphar Sp. z o.o. from a group of private shareholders in a cash transaction. The company’s founder and long-term CEO will stay with Symphar post-acquisition to oversee its seamless integration in the Farmak group and support the consolidation of Farmak’s Polish operations into a single entity. The deal was closed after fulfilling a set of conditions precedent by Farmak and the sellers.
“Today starts a new chapter for Farmak and Symphar. We’re looking forward to working with our new team members to grow our combined business and keep providing reliable treatments to patients and caregivers in Poland” said Viktor Kostiuk, CEO at Farmak AG
The deal marks Farmak’s second M&A in the market since 2016 when the initial presence was established. Farmak continues as the only Ukrainian pharmaceutical company with a sizeable footprint in Poland, the largest pharmaceutical market in CEE region.
The acquisition of Symphar is the second transaction for FinPoint as a financial adviser to Farmak and the first buy-side advisory work related to a Polish target. Following last year’s advice on the acquisition of pharmaceutical marketing companies in the Czech Republic and Slovakia, the transaction comes as a continuation of FinPoint’s mandate to support our client’s global expansion.
FinPoint acted as exclusive financial adviser to Farmak. The company was represented by Oleg Kovtun, Roman Menshov, and Yurii Filipovych.
About Symphar
Symphar is a Polish pharmaceutical company with its offices in Warsaw. Its team of 90 professionals works with more than 50 products in the diabetology, gynecology, psychiatry, neurology, and other therapeutic areas. In 2023, Symphar reached over €22 million revenue following its long-lasting period of stable and profitable growth.
About Farmak
Farmak, an international pharmaceutical company established in 1925, operates with a focus on research and development, manufacturing, and global sales and marketing of generics. With manufacturing and R&D facilities in Ukraine and Spain, Farmak has reached a strong presence globally. The company owns 10 commercial offices strategically positioned around the world, including Ukraine, Poland, the Czech Republic, the Slovak Republic, Central Asia, the Asia Pacific region, the Middle East, and Western Europe.